WALTHAM, Mass., June 25 /PRNewswire/ — Millennium Research Group (MRG) conducted a detailed survey of over 140 US and European based urologists during the recent 2008 American Urological Association (AUA) Annual Meeting. Results of this study are analyzed in the US and European Urologist Survey: Prostate Cancer Treatment Trends 2008 report. Data from the study suggests that several minimally invasive prostate cancer Treatment options are underused in both the US and Europe.
US urologists indicated that cryosurgery was underused, while European urologists felt that both cryosurgery and high-intensity focused ultrasound (HIFU) were underused. In both regions, insufficient data supporting the treatments and the need to refer patients to another specialist were considered the leading barriers to adoption.
“These barriers will need to be addressed before utilization rates can increase notably,” says Barbara Prud’homme, Senior Analyst at Millennium Research Group. “Expensive equipment, poor results with early cryosurgery equipment, and physician familiarity with traditional treatments such as radical prostatectomy, have deterred many from performing these minimally invasive procedures. Moreover, many urologists see cryosurgery as a salvage operation after other treatments haven’t worked. One positive sign for the adoption of these treatments is that US and European urologists indicated that their use of these treatments had increased over the past year.”
Although urologists were underusing new minimally invasive treatments, they were aware of emerging Treatment options, including gene therapy and autoimmune therapy. Urologists believed emerging treatments would eventually improve patient outcomes.
MRG’s US and European Urologist Survey: Prostate Cancer Treatment Trends 2008 report examines urologists’ opinions on some of the industry’s most discussed technologies, including permanent implant brachytherapy, high dose rate (HDR) brachytherapy, cryotherapy, and HIFU.
About Millennium Research Group
Millennium Research Group (), a Decision Resources, Inc. company (), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized consulting services.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:

Amy Krohn
Millennium Research Group
416-364-7776 x101

Millennium Research Group

NEW ORLEANS, June 15 /PRNewswire-FirstCall/ — Taking innovation and efficiency to the next level, Siemens Healthcare () announces the next big thing in SPECT imaging: “intelligence.” At the 2008 Society of Nuclear Medicine Annual Meeting, June 14-18, in New Orleans, IQ- SPECT (Works in Progress) takes center stage as Siemens newest Symbia(R) feature that enables a comprehensive cardiac evaluation including perfusion, attenuation correction and calcium scoring in just five minutes**.
(Logo: )
“This exciting new Symbia feature is really all about added value and optimization. IQ-SPECT improves the performance of the Symbia by allowing it to become organ specific and provide complete cardiac evaluations with an extremely quick turnaround time,” says Michael Reitermann, chief executive officer, Molecular Imaging, Siemens Medical Solutions USA, Inc. “And because of its speed and versatility, IQ-SPECT offers enhanced cardiac image quality and thus offers physicians more confident diagnostic ability because of decreased patient movement. We expect this new capability to provide organ specific, cardiac imaging on general purpose systems, as it could potentially expand to other organs as well.”
IQ-SPECT technology is achieved with SMARTZOOM, a specially designed “smart” collimator that magnifies the heart while imaging the rest of the torso under traditional conditions. Typically, cardiac SPECT data is obtained through keeping the detectors positioned at 90 degrees and as close to the body as possible, utilizing mechanically centered detector rotation, where organ specific magnification cannot be achieved. The flexible mechanics of the Symbia S and T gantries allow an organ centric detector rotation that can zero-in on the organ of interest; in this case, the heart. Combining this organ centric orbit acquisition technique, fast, 3D iterative reconstruction that is optimized for more confident diagnoses, and improved patient comfort from a quicker scan, IQ-SPECT will set the standard for image quality, speed, productivity and throughput.
IQ-SPECT will be available for all new Symbia S and T systems, and is field upgradeable for any existing Symbia S or T systems that are already widely available in leading hospitals and imaging centers across the globe. The new SMARTZOOM feature is seamlessly integrated into the current Symbia workflows and automation features, giving users access to the most flexible and versatile system available today. From a user perspective, IQ-SPECT is fully automated and can therefore accommodate more patients per day and meet a variety of patient needs. For example, pediatric patients can benefit from a lower injected dose in regular acquisition time, or from less motion and more comfort with a regular dose and quicker acquisition time. A quicker scan allows for less patient movement and lowers the probability of retakes.
Using traditional SPECT systems, cardiac perfusion studies average about 15 to 20 minutes, limiting the amount of patients per day. With an “intelligent” Symbia IQ-SPECT imager, more patients can be scanned per day in much less time; as little as four minutes per patient for a full cardiac work- up.
Raising the bar even higher in well-established myocardial perfusion SPECT imaging evaluations is possible with hybrid Symbia SPECT-CT and IQ-SPECT. The addition of calcium scoring, extracted from a quick low-dose spiral CT scan that is also used to obtain attenuation correction information, is becoming a critical element in the cardiac work-up to screen patients for coronary artery disease (CAD). It can improve the risk stratification of patients who are at intermediate to high risk. Calcium scoring is an independent indicator of prognosis in CAD and in combination with SPECT, does improve diagnostic confidence.
Adding the 30-second CT to the SPECT study can not only illustrate any ischemia present in the patient, but also can assess the buildup of calcium in the coronary arteries. Because many heart attacks occur in patients without obvious signs or risk factors, calcium scoring can definitively screen for and detect CAD. The addition of IQ-SPECT to SPECT-CT studies may lead to new risk stratification algorithms and work-ups for patients with suspected CAD.
About Siemens Healthcare
Siemens Healthcare is one of the world’s largest suppliers to the healthcare industry. The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Healthcare is the first fully integrated diagnostics company, bringing together imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services. Siemens Healthcare delivers solutions across the entire continuum of care - from prevention and early detection, to diagnosis, therapy and care. Additionally, Siemens is the global market leader in innovative hearing instruments. The company employs more than 49,000 people worldwide and operates in 130 countries. In the fiscal year 2007 (Sept. 30), Siemens Healthcare reported sales of euro 9.85 billion, orders of euro 10.27 billion, and group profit of euro 1.32 billion. Further information can be found by visiting .
* Works In Progress. The information about the product is preliminary.
The product is under development and is not commercially available in
the United States, and its future availability cannot be ensured.

** New product feature based on preliminary internal data. Actual
performance characteristics have not been established.

Siemens Healthcare

PALO ALTO, Calif., May 27 /PRNewswire-FirstCall/ — Varian Medical Systems and Still River Systems, Inc. today announced an agreement to develop an interface between Varian’s ARIA(TM) Oncology Information System and Still River’s Monarch250(TM) Proton Beam Radiotherapy (PBRT) System.
“ARIA is a powerful oncology information system that manages the clinical processes unique to radiotherapy treatments for cancer,” said Corey Zankowski, Varian’s senior director for product management. “In addition to providing a complete electronic medical record for oncology, ARIA is exceptional at recording and verifying the numerous Treatment parameters and instruction sets required for complex radiotherapy treatments. Varian is committed to creating a completely open environment and ensuring connectivity between ARIA and most commonly-used radiation delivery devices, including proton Treatment systems. As such, Varian is pleased to be developing, with the support of Still River, an interface with the Monarch250 proton therapy system.”
“It is Varian’s aim to bring the familiar workflow, look and feel of ARIA into the proton environment, to ease the transition of staff from conventional radiotherapy to proton therapy,” adds James DeFilippi, Varian’s business manager for integrated proton solutions.
Still River Systems will provide technical assistance to Varian engineers, who will develop the interface to allow important “record and verify” functionality across the two systems.
“We are developing the Monarch250 proton therapy system to support existing clinical processes. The Monarch250 ARIA interface will allow cancer centers to integrate proton therapy within their existing radiation therapy practices,” adds Skip Rosenthal, PhD, Still River Systems vice president, clinical systems.
Any new ARIA interface that facilitates “record and verify” functions with new radiotherapy delivery technologies are subject to 510(k) clearance by the FDA, and would need such clearance prior to any clinical deployment.
About Still River Systems
Still River Systems, based in Littleton, Massachusetts, is dedicated to providing physicians and their patients access to high quality, cost-effective proton therapy solutions, and to help establish this superior Treatment modality as a standard of care for patients worldwide. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment. This system has not yet been cleared by the FDA for commercial use in clinical therapy. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540- 1500 or visit their website @ .
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,600 people who are located at manufacturing sites in North America and Europe and in its 60 sales and support offices around the world. For more information, visit .
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a “safe harbor” for these types of statements. These forward-looking statements regarding future business, events, plans, objectives, expectations, and other similar matters, including, but not limited to, statements using the terms “is committed to creating,”"ensuring,” and “are developing,”"will allow,” and “would need” are subject to risks and uncertainties that could cause the actual results of Varian Medical Systems, Inc. to differ materially from management’s current expectations. These risks and uncertainties include, without limitation, product demand and market acceptance risks; technological innovation, development of new generation of products and enhancements to existing products; the ability to procure appropriate FDA clearances for new products; and other risks detailed in Varian Medical Systems, Inc. filings with the Securities and Exchange Commission. Varian Medical Systems, Inc. assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact: Meryl Ginsberg
Varian Medical Systems
650-424-6444

Varian Medical Systems

MOUNT VERNON, Wash., May 20 /PRNewswire/ — PreViser Corporation (), a Washington State-based provider of patented oral disease and risk assessment technology to the dental profession, announced today the finalization of a licensing agreement with Oral Health Innovations (OHI) Ltd () of Birmingham, England to market PreViser technology to dentists within the United Kingdom and the Republic of Ireland.
OHI Ltd is a joint venture with the University of Birmingham. Following a successful pilot, OHI will launch PreViser at a Denplan-sponsored seminar for its Excel accredited practitioners in June 2008. Discussions are also underway with a number of Primary care Trusts on how the technology can be used as a best practice tool within National Health Service (NHS) dentistry.
Iain Chapple, Professor of Periodontology and Consultant in Restorative Dentistry, who runs an NHS referral center serving approximately six million patients, acts as adviser to OHI Ltd. Prof. Chapple commented, “PreViser is unique in its web-based approach to risk and disease scoring and has a scientific evidence base behind its efficacy. However, one of its biggest benefits is the immediate and personalized biofeedback it offers to patients. We all know that successful periodontal therapy is founded on patient education and compliance with home care regimes. PreViser is a most innovative tool that motivates patients to take personal responsibility for their own oral health.
“In addition to the obvious patient and practitioner benefits, PreViser allows oral healthcare funders to focus their resources towards those that need it most and provides a platform from which to deliver truly preventative oral care in a cost effective manner.
“As a teacher, it is exciting to be able to utilize the system, which is provided free of charge to Dental Education establishments for educational purposes. The interactive nature of the platform is something dental students actively engage in and learn from. I would encourage every dental school to take advantage of this technology.”
PreViser Corporation provides web-enabled diagnostic decision support tools for dentists and dental hygienists. The PreViser Oral Health Information Suite(TM) enables quick, accurate, reproducible and objective diagnosis and analysis of oral disease risk in an easy-to-understand format for the professional and the patient.
A percentage of profits of OHI Ltd go to the Oral & Dental Research Trust of the UK and a research fellowship at the University of Birmingham.
*(LOGO 72dpi: Send2Press.com/mediaboom/08-0520-PreViser_72dpi.jpg)

For further information contact:

Oral Health Innovations Ltd: Liz Chapple,

PreViser Corporation: Carl Loeb, 360-941-4715,
This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).
PreViser Corporation

SUN VALLEY, Calif., May 19 /PRNewswire-FirstCall/ — XTend Medical Corporation (Pink Sheets: XMDC) announced today the company will be adding a complete line of nutritional products aimed at capturing a portion of the Billion Dollar Medical Nutrition Sector.
The company, working in close partnership with several major manufacturers, will offer a complete line of nutritional products for patients suffering from complications and/or circumstances that prevent them from achieving proper nutrition levels to improve their daily care in managing their diabetes.
“As the company continues to move forward in delivering our Remote Patient Monitoring System, we felt it was a strong move for the company to expand our product lines to include nutritional products that will allow the company to increase sales within the diabetes sector we’re targeting. As we work with individual doctors, healthcare organizations, and clinics throughout the U.S., the ability for the company to offer the best in nutritional supplements will allow us to expand our sales opportunities to fill patient needs to properly maintain their health requirement guidelines established by their provider. The company will be selling the products through our sales staff directly to providers as well as through our online store that will be launched in the month of June. We feel that by adding nutrition products to our mix, we can continue to gain sales and assist the company in opening up additional revenue streams within our business model,” stated Mr. Paul D. Lisenby, CEO of XTend Medical.
For any healthcare agency of physician group that would like to find more about the how XTend can assist in your management of diabetic patients, please visit the company website at or email us at
About XTend Medical:
XTend Medical Corporation markets and sells healthcare and wellness products to hospitals, managed care companies, nursing homes, physician groups and individual patients. XTend has developed a complete Remote Diabetic Patient Monitoring System that is currently being used by physicians and other healthcare agencies throughout the U.S. Through their alliances, XTend offers pharmacy services, diabetic supplies, and telemedicine products that increase patient care yet reduce costs associated with servicing those patients. For more information, please visit their website at http://www.xtendmedical.com
Safe Harbor
This press release contains or may contain forward-looking statements such as statements regarding the Company’s growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.
Contact: FutureTechIR for XTend Medical Corporation
Investor Relations
(817) 812-2105

XTend Medical Corporation

ARLINGTON, Texas, May 13 /PRNewswire/ — Veria — a growing natural health and wellness company combining Veria TV (a 24×7 HD television network), local wellness centers, and a lifestyle-focused website — today announced its acquisition of Scottsdale, Ariz.-based Massage Envy Ltd., LLC. Massage Envy is America’s leading provider of therapeutic massage services, with 420 clinics open nationwide.David Humphrey, President of Veria and newly appointed Chief Executive Officer of Massage Envy, said, “Massage Envy has a tremendous network of clinic staff, franchisees, and regional developers, and an experienced management team. The company’s rapid growth has been remarkable, and we expect to help accelerate that growth even further.”"We’ll also look for opportunities to incorporate Veria TV — a powerful platform for educating consumers about the physical and emotional benefits of massage — into the Massage Envy community. In addition, Veria can provide Massage Envy franchisees with an exceptional range of natural health and wellness products to offer their clients,” Humphrey added.Veria’s acquisition of Massage Envy underscores the continued development of the therapeutic massage industry. Massage Envy, which has been at the forefront of the industry’s growth, was founded in 2002 by former CEO John Leonesio, and has grown to 420 clinics operating in 36 states. The company has another 350 clinics already in development nationwide. Massage Envy is the single largest employer of licensed professional massage therapists, with more than 8,000 therapists providing massage every week.”Massage Envy will help more than one million Americans this year relieve stress, work out everyday aches and pains, and relax,” said Leonesio. “Veria’s fast-paced growth, focus on natural wellness, and integrated lifestyle business model can perfectly complement and accelerate our own rapid expansion. I’m convinced Veria’s contributions will take Massage Envy and its franchise network to an even higher level of success.” Leonesio will remain with Massage Envy as a corporate director.Veria is part of the Essel Group of companies, a multi-billion-dollar consortium encompassing television networks, cable systems, satellite communications, entertainment enterprises, and one of the world’s largest packaging companies. Subhash Chandra, Chairman of the Essel Group and founder of Veria, commented that “Veria is committed to supporting consumers’ growing interest in a natural wellness lifestyle. Massage is an essential part of a healthy lifestyle, and Massage Envy brings the benefits of massage to thousands more Americans every month by making it convenient and affordable. We are proud to welcome Massage Envy to the Essel family.”The acquisition includes Massage Envy Ltd., LLC, and its affiliates Massage Elements, LLC and Massage EN V, LLC.Sagent Advisors Inc., an independent, privately-owned investment bank, initiated this transaction and served as financial advisor to Veria. Edgeview Partners, a subsidiary of CIT Capital Securities, LLC, advised Massage Envy during the transaction. THERAPEUTIC MASSAGE INDUSTRY BY THE NUMBERS * Between August 2006 and June 2007, almost a quarter of Americans (24 percent) had a massage at least once. * Forty-three percent of women and 25 percent of men have had a massage in the last five years. * Of these people, 30 percent report they did so for health conditions. * Eighty-five percent agree that massage can be beneficial to health and wellness. * According to the U.S. Department of Labor, employment of massage therapists is expected to increase 20 percent from 2006 to 2016, faster than average for all occupations. - American Massage Therapy Association About VeriaVeria is the primary consumer brand of Natural Wellness USA, Inc. (NWUSA), a member of the Essel Group of companies. Veria combines three major wellness businesses. Veria TV is a new high-definition television network of original natural wellness lifestyle programming, available on Channel 9575 on DISH Network(TM). Veria Wellness Centers offer wellness spa services, yoga and other classes, and a wide range of natural products including NWUSA’s exclusive Veria and Chandra brands. Some Wellness Centers also feature a Natural Foods Cafe. Veria.com is both a leading source of information on the natural wellness lifestyle and a major online shopping destination for natural products.About Massage EnvyMassage Envy Limited, LLC is a national franchise of massage clinics dedicated to providing professional and affordable therapeutic massage services to consumers with busy lifestyles at convenient times and locations. Founded in 2002, Massage Envy has opened 420 clinics in 36 states in just over five years, with 350 more franchises currently under development from coast to coast. Veria

PARSIPPANY, N.J., May 13 /PRNewswire/ — Ferring Pharmaceuticals Inc. has announced that EUFLEXXA(R) (1% sodium hyaluronate), its hyaluronic acid (HA) therapy for the pain of knee osteoarthritis, will serve as a sponsor for the Babolat World Tennis Classic.The Babolat World Tennis Classic is a Category II United States Tennis Association sanctioned tournament held in Rancho Mirage, CA for men and women aged 35-85. The largest adult tennis tournament of its kind in the world, most recently the Classic featured a record 770 matches with entrants representing 35 states and five foreign countries.”We are excited to be part of such an amazing event,” said Alex Drigan, Product Director for EUFLEXXA(R). “Tennis is a lifelong sport that helps keep people healthy and active. We strongly believe in events that offer people an opportunity to enjoy competitive athletics later in life.”Entering its 22nd year, the 2009 Babolat Tennis World Classic will be held from January 25 to February 1 at the Mission Hills Country Club in Rancho Mirage, CA.About EUFLEXXA(R)EUFLEXXA(R) (1% sodium hyaluronate) is the first and only non-avian derived hyaluronic acid approved in the U.S. for the Treatment of pain caused by knee osteoarthritis and continues to be the fastest growing brand of HA on the market.(1) EUFLEXXA(R) is indicated for a three-injection Treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). In a prospective, randomized, double-blind, head-to-head study versus the market leading HA therapy, significantly more patients were “pain-free” and “symptom-free” with EUFLEXXA(R).(2)The process used to manufacture EUFLEXXA(R) produces the HA that most closely resembles the HA in healthy human synovial fluid and the most highly purified HA product available today. In addition, since it is not derived from an avian source (chicken or rooster combs), the risk of reactions related to avian proteins is eliminated.(3-8)EUFLEXXA(R) received PMA approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005. For more information, visit .About Ferring Pharmaceuticals Inc.Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring’s line of orthopaedic products includes EUFLEXXA(R), hyaluronic acid for pain from osteoarthritis in the knee.Ferring also markets BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) (menotropins for injection, USP) and REPRONEX(R) (menotropins for injection, USP), Novarel(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the Treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R)/DS for the relief of discomfort of the lower urinary tract.The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit .Important Treatment ConsiderationsEUFLEXXA(R) (1% sodium hyaluronate) is indicated for the Treatment of knee pain due to osteoarthritis (OA). It is used in people who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy. EUFLEXXA(R) should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site. In a randomized, double-blind, multicenter clinical trial, the only adverse events reported with EUFLEXXA(R) at an incidence of 5% or greater were arthralgia (joint pain) (8.75%) and back pain (5%). Temporary knee pain and swelling may occur after injection with EUFLEXXA(R). The safety and effectiveness of injecting EUFLEXXA(R) into the knee together with other injectable medications or into joints other than the knee have not been studied. The safety and effectiveness of Treatment cycles of fewer than 3 injections or of repeated Treatment cycles with EUFLEXXA(R) have not been established. Strict aseptic technique must be followed to avoid joint infection.It is recommended to avoid strenuous activity or prolonged weight-bearing activities such as jogging or tennis within 48 hours following intra-articular injection. 1 IMS National Sales Perspective Data, February 2008 2 Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the Treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006; 14: 154-162. 3 Schiavinato A, Finesso M, Cortivo R, & Abatangelo G. Comparison of the effects of intra-articular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin Exp Rheumatol. 2002; 20: 445-454. 4 Goomer RS, Leslie K, Maris T, & Amiel D. Native hyaluronan produces less hypersensitivity than cross-linked hyaluronan. Clin Orthop Relat Res. 2005; 434: 239-245. 5 Leopold SS, Warme WJ, Pettis PD, & Shott S. Increased frequency of acute local reaction to intra-articular hylan GF-20 (synvisc) in patients receiving more than one course of treatment. J Bone Joint Surg Am. 2002; 84-A: 1619-1623. 6 Puttick MP, Wade JP, Chalmers A, Connell DG, & Rangno KK. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol. 1995; 22: 1311-1314. 7 Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, & Schumacher HR. Are there distinctive inflammatory flares after hylan g-f 20 intraarticular injections? J Rheumatol. 2002; 29: 2611-2614. 8 Chen AL, Desai P, Adler EM, & Di Cesare PE. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am. 2002; 84-A: 1142-1147.Ferring Pharmaceuticals Inc.

ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ — InforMedix Holdings, Inc. (BULLETIN BOARD: IFMX) , announced that Boothwyn Pharmacy, a visionary pharmacy that sells medication adherence services to senior independent living centers, pharmaceutical companies, managed care organizations, and consumers, will be marketing and selling Med-ePhone and Med-eMonitor products and services to its existing client base. Boothwyn has pioneered the use of pharmacist consultants to provide medication adherence services, diabetes care products, durable medical equipment, and pharmaceutical compounding.According to Louis Micolucci, President of Boothwyn Pharmacy, “We are excited to add the Med-ePhone and Med-eMonitor products to Boothwyn’s ongoing services to improve medication adherence for senior citizens in independent living centers, women with high risk pregnancies monitored through pharmaceutical company programs, and managed care patients. These products from InforMedix will significantly increase the value of the services Boothwyn already offers under existing contracts with our customers, and should allow us to expand our business under new contracts. According to a report from MIT’s Sloan School of Management, through improving its customers’ medication adherence by 25%, a community pharmacy can increase gross revenues by $1.7 million and gross profits by $400,000 each year. We believe that through our aggressive marketing of InforMedix’s products, that Boothwyn will significantly increase its revenues through the improved medication adherence of our customers, which will also further our mission of being at the forefront of improved communications methods to create greater patient outcomes.”Mr. Micolucci went on to state, “We are extremely impressed with the scientific studies validating InforMedix’s Med-eXpert System, which links consumers, their loved ones, pharmacists, and care managers to improve medication adherence and health. We intend to distribute Med-ePhone and Med-eMonitor to our existing institutional customers and consumers, and then use these products along with other services we provide to expand our customer base. As a pharmacy that has pioneered methods to improve the care of our consumer customers and our institutional clients, we look forward to advancing this important tradition through our partnership with InforMedix.”Bruce A. Kehr, M.D, chairman and Chief Executive Officer of InforMedix commented, “We are extremely pleased to be partnering with Louis Micolucci and Boothwyn Pharmacy. Louis is a visionary pharmacy entrepreneur who has extended advanced medication adherence services well beyond his consumer base to a number of institutions. We are highly impressed with his business operation and facility, which is beautifully designed, and filled with contrasting symbols of pharmacy practice from past centuries and the high-tech self-care products of today.”About Boothwyn PharmacyEstablished in 1933, Boothwyn Pharmacy Inc., believes that the patient, doctor, pharmacist relationship is the cornerstone of quality healthcare. Services provided include retail prescriptions, customized compounded medications, institutional pharmaceutical needs for its geriatric population, and home health care medical equipment and supplies. Boothwyn Pharmacy, Inc. places itself at the forefront of bringing together innovative practices, state-of-the-art technology and improved communication methods to create greater patient outcomes. Additional services include the provision of pharmaceutical and medical supply services to retail customers as well as those patients with specialized needs in home-care or long-term care settings.About InforMedixInforMedix, Inc., “The Medication Adherence Solution,” is based in Rockville, Maryland. The Company has brought to market its Med-eXpert System for consumer product and disease management markets, which use Med-ePhone and Med-eMonitor units to deliver peace-of-mind, improved independent living, and better health outcomes to patients and their loved ones. The Med-ePhone(TM) System (in testing) prompts, monitors and records medication adherence and health status assessment delivered to patients over mobile phones and landlines using Interactive Voice Response Systems (IVRS), combined with 24/7 monitoring. The Med-eMonitor System (”Medication, Safe and Easy” (TM)) integrates a portable patient-interactive “smart pillbox,” hardware, software, and 24/7 monitoring. Both products are designed to enable chronically ill patients and their loved ones, professionals in disease management programs, and medical researchers to efficiently monitor and manage medication and care plan adherence, clinical response, and drug safety. For more information, visit .Safe Harbor StatementThis press release may contain forward looking statements that involve risks and uncertainties, including statements regarding our business strategy and development plans, expectations regarding increased sales and/or revenues, plans for entering into new businesses, anticipated sources and uses of funds and other statements regarding our plans, objectives, expectations and intentions that are not historical facts. Because these forward-looking statements involve risks and uncertainties, actual results could differ materially from those discussed in this press release. These risks and uncertainties are described in greater detail in the reports that we file with the Securities and Exchange Commission. Our actual results, performance or achievements may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements reflect our beliefs and expectations as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. InforMedix Holdings Inc.